Cargando…
A New Peritoneal Dialysis Solution Containing L-Carnitine and Xylitol for Patients on Continuous Ambulatory Peritoneal Dialysis: First Clinical Experience
Peritoneal dialysis (PD) is a feasible and effective renal replacement therapy (RRT) thanks to the dialytic properties of the peritoneal membrane (PM). Preservation of PM integrity and transport function is the key to the success of PD therapy, particularly in the long term, since the prolonged expo...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996173/ https://www.ncbi.nlm.nih.gov/pubmed/33668249 http://dx.doi.org/10.3390/toxins13030174 |
_version_ | 1783670057110339584 |
---|---|
author | Rago, Carmela Lombardi, Teresa Di Fulvio, Giorgia Di Liberato, Lorenzo Arduini, Arduino Divino-Filho, José C. Bonomini, Mario |
author_facet | Rago, Carmela Lombardi, Teresa Di Fulvio, Giorgia Di Liberato, Lorenzo Arduini, Arduino Divino-Filho, José C. Bonomini, Mario |
author_sort | Rago, Carmela |
collection | PubMed |
description | Peritoneal dialysis (PD) is a feasible and effective renal replacement therapy (RRT) thanks to the dialytic properties of the peritoneal membrane (PM). Preservation of PM integrity and transport function is the key to the success of PD therapy, particularly in the long term, since the prolonged exposure to unphysiological hypertonic glucose-based PD solutions in current use is detrimental to the PM, with progressive loss of peritoneal ultrafiltration capacity causing technique failure. Moreover, absorbing too much glucose intraperitoneally from the dialysate may give rise to a number of systemic metabolic effects. Here we report the preliminary results of the first clinical experience based on the use in continuous ambulatory PD (CAPD) patients of novel PD solutions obtained through partly replacing the glucose load with other osmotically active metabolites, such as L-carnitine and xylitol. Ten CAPD patients were treated for four weeks with the new solutions. There was good tolerance to the experimental PD solutions, and no adverse safety signals were observed. Parameters of dialysis efficiency including creatinine clearance and urea Kt/V proved to be stable as well as fluid status, diuresis, and total peritoneal ultrafiltration. The promising tolerance and local/systemic advantages of using L-carnitine and xylitol in the PD solution merit further research. |
format | Online Article Text |
id | pubmed-7996173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79961732021-03-27 A New Peritoneal Dialysis Solution Containing L-Carnitine and Xylitol for Patients on Continuous Ambulatory Peritoneal Dialysis: First Clinical Experience Rago, Carmela Lombardi, Teresa Di Fulvio, Giorgia Di Liberato, Lorenzo Arduini, Arduino Divino-Filho, José C. Bonomini, Mario Toxins (Basel) Article Peritoneal dialysis (PD) is a feasible and effective renal replacement therapy (RRT) thanks to the dialytic properties of the peritoneal membrane (PM). Preservation of PM integrity and transport function is the key to the success of PD therapy, particularly in the long term, since the prolonged exposure to unphysiological hypertonic glucose-based PD solutions in current use is detrimental to the PM, with progressive loss of peritoneal ultrafiltration capacity causing technique failure. Moreover, absorbing too much glucose intraperitoneally from the dialysate may give rise to a number of systemic metabolic effects. Here we report the preliminary results of the first clinical experience based on the use in continuous ambulatory PD (CAPD) patients of novel PD solutions obtained through partly replacing the glucose load with other osmotically active metabolites, such as L-carnitine and xylitol. Ten CAPD patients were treated for four weeks with the new solutions. There was good tolerance to the experimental PD solutions, and no adverse safety signals were observed. Parameters of dialysis efficiency including creatinine clearance and urea Kt/V proved to be stable as well as fluid status, diuresis, and total peritoneal ultrafiltration. The promising tolerance and local/systemic advantages of using L-carnitine and xylitol in the PD solution merit further research. MDPI 2021-02-24 /pmc/articles/PMC7996173/ /pubmed/33668249 http://dx.doi.org/10.3390/toxins13030174 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Rago, Carmela Lombardi, Teresa Di Fulvio, Giorgia Di Liberato, Lorenzo Arduini, Arduino Divino-Filho, José C. Bonomini, Mario A New Peritoneal Dialysis Solution Containing L-Carnitine and Xylitol for Patients on Continuous Ambulatory Peritoneal Dialysis: First Clinical Experience |
title | A New Peritoneal Dialysis Solution Containing L-Carnitine and Xylitol for Patients on Continuous Ambulatory Peritoneal Dialysis: First Clinical Experience |
title_full | A New Peritoneal Dialysis Solution Containing L-Carnitine and Xylitol for Patients on Continuous Ambulatory Peritoneal Dialysis: First Clinical Experience |
title_fullStr | A New Peritoneal Dialysis Solution Containing L-Carnitine and Xylitol for Patients on Continuous Ambulatory Peritoneal Dialysis: First Clinical Experience |
title_full_unstemmed | A New Peritoneal Dialysis Solution Containing L-Carnitine and Xylitol for Patients on Continuous Ambulatory Peritoneal Dialysis: First Clinical Experience |
title_short | A New Peritoneal Dialysis Solution Containing L-Carnitine and Xylitol for Patients on Continuous Ambulatory Peritoneal Dialysis: First Clinical Experience |
title_sort | new peritoneal dialysis solution containing l-carnitine and xylitol for patients on continuous ambulatory peritoneal dialysis: first clinical experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996173/ https://www.ncbi.nlm.nih.gov/pubmed/33668249 http://dx.doi.org/10.3390/toxins13030174 |
work_keys_str_mv | AT ragocarmela anewperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience AT lombarditeresa anewperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience AT difulviogiorgia anewperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience AT diliberatolorenzo anewperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience AT arduiniarduino anewperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience AT divinofilhojosec anewperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience AT bonominimario anewperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience AT ragocarmela newperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience AT lombarditeresa newperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience AT difulviogiorgia newperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience AT diliberatolorenzo newperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience AT arduiniarduino newperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience AT divinofilhojosec newperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience AT bonominimario newperitonealdialysissolutioncontaininglcarnitineandxylitolforpatientsoncontinuousambulatoryperitonealdialysisfirstclinicalexperience |